Clinical trial
Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell…
NCT00216138 · Hoosier Cancer Research Network, Other · Terminated
Key facts
| NCT number | NCT00216138 |
|---|---|
| Title | Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck |
| Official title | A Single Arm Phase II Trial of Docetaxel and Capecitabine for the First Line Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN): Hoosier Oncology Group HN02-40 |
| Lead sponsor | Hoosier Cancer Research Network, Other |
| Collaborators | Sanofi Industry Hoffmann-La Roche Walther Cancer Institute |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Capecitabine, Premedication |
| Enrollment | 19 |
| Start date | Mar 1, 2004 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | May 2, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: